WASHINGTON, July 7 — The figure that matters: 6.7 million. That is the number of Americans aged 65 and older living with Alzheimer’s disease in 2023, according to the Alzheimer’s Association’s 2023 Facts and Figures report. By 2060, barring medical breakthroughs, that number is projected to hit 13.8 million.
The bottom line: Alzheimer’s is the seventh-leading cause of death in the United States. It is a progressive neurodegenerative disorder and the most common cause of dementia, accounting for 60-80% of all dementia cases.
Investors will note the sheer scale of the patient population — and the costs that come with it.
By the numbers
The total cost of caring for individuals with Alzheimer’s and other dementias in the U.S. is estimated at $345 billion in 2023. That figure includes Medicare and Medicaid payments. The disease is characterized by the accumulation of amyloid beta plaques and tau protein tangles in the brain, leading to neuronal death and cognitive decline.
Alzheimer’s is not a single disease mechanism but a complex cascade. The plaques and tangles disrupt communication between neurons and trigger inflammatory responses.
Neurons die. Brain tissue shrinks. Memory, thinking, and behavior deteriorate progressively.
The cost trajectory
The $345 billion figure represents direct costs to the healthcare system. It does not capture the full economic burden, including unpaid caregiving by family members. As the population ages, those costs will rise in lockstep with the projected increase in cases — from 6.7 million today to 13.8 million by 2060.
That projection assumes no major therapeutic breakthroughs alter the disease’s trajectory. Researchers are actively pursuing treatments targeting amyloid beta and tau proteins, but no cure exists.
The Alzheimer’s Association report serves as a baseline for policymakers and investors tracking the disease’s economic impact. The disease accounts for 60-80% of dementia cases, making it the dominant form of cognitive decline in the aging population. Other dementias include vascular dementia, Lewy body dementia, and frontotemporal disorders, but Alzheimer’s remains the primary driver of dementia-related costs and mortality.
What to watch
Investors will track clinical trial data from companies developing anti-amyloid and anti-tau therapies. The 13.8 million projection by 2060 represents both a public health challenge and a potential market opportunity. Any breakthrough that delays onset or slows progression would dramatically alter those numbers — and the $345 billion cost figure.
Policymakers face a growing fiscal pressure as Medicare and Medicaid absorb a significant share of Alzheimer’s care costs. The 2023 report provides the data foundation for budget projections and research funding decisions. Consult your doctor for medical advice.
